Xelopes 40 mg/vial (IV Injection)

40 mg vial: ৳ 90.27

Medicine Details

Category	Details
Generic	Omeprazole
Company	Beacon pharmaceuticals plc
Also available as	Xelopes 20 mg capsule Xelopes 40 mg capsule

Indications

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
Prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

Pharmacology

Inhibitor of gastric acid secretion, blocks hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system, onset of antisecretory effect occurs within one hour, maximum effect within two hours, inhibition of secretion lasts up to 72 hours, secretory activity returns gradually over 3 to 5 days after discontinuation.

Dosage

20 mg once daily for benign gastric and duodenal ulcer
40 mg once daily for severe or recurrent cases
10-20 mg daily for long-term management of acid reflux disease
10-20 mg once daily for acid-related dyspepsia
40 mg on the preceding evening, then 40 mg 2-6 hours before surgery for prophylaxis of acid aspiration
20-120 mg daily for Zollinger-Ellison syndrome
Omeprazole is recommended at a dose of 20 mg twice daily for Helicobacter pylori eradication regimen in peptic ulcer disease
Pediatric use: 10-20 mg once daily for 4-12 weeks (body-weight 10-20 kg), 20-40 mg once daily for 4-12 weeks (body-weight over 20 kg)
IV Injection: 40 mg slowly as an intravenous injection, one hour before surgery for prophylaxis of acid aspiration

Administration

Omeprazole IV injection should be given as a slow intravenous injection, the solution for IV infusion should be given over a period of 20-30 minutes or more, must not be given by any other route, reconstituted solution should not be mixed with any other drug.

Interaction

Decreased intragastric acidity may reduce the absorption of ketoconazole, can delay the elimination of diazepam, phenytoin and warfarin, monitoring of patients receiving warfarin or phenytoin is recommended, plasma concentrations of Omeprazole and clarithromycin are increased during concomitant administration, no evidence of interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, cyclosporin, lidocaine, quinidine, estradiol, amoxycillin, antacids, piroxicam, diclofenac, naproxen, absorption not affected by alcohol or food, simultaneous treatment with digoxin leads to a 10% increase in the bioavailability of digoxin.

Contraindications

Contraindicated in patients with known hypersensitivity to it, possibility of malignancy should be excluded before treatment with omeprazole is instituted when gastric ulcer is suspected.

Side Effects

Skin rash, urticaria, and pruritus
Photosensitivity, bullous eruption, erythema multiforme, angioedema, and alopecia
Diarrhea and headache
Gastrointestinal reactions including constipation, nausea/vomiting, flatulence, and abdominal pain
Dry mouth, stomatitis, and candidiasis
Paraesthesia
Dizziness, light headedness, and feeling faint
Somnolence, insomnia, and vertigo
Reversible mental confusion, agitation, depression, and hallucinations
Arthritic and myalgic symptoms
Blurred vision, taste disturbance, peripheral edema, increased sweating, gynaecomastia, leucopenia, thrombocytopenia, agranulocytosis, pancytopenia, anaphylactic shock, malaise, fever, bronchospasm, encephalopathy in patients with pre-existing severe liver disease, hepatitis with or without jaundice, interstitial nephritis, hepatic failure, increases in liver enzymes observed

Pregnancy & Lactation

No adverse effects of Omeprazole on pregnancy or on the health of the fetus/newborn child, use during pregnancy is safe, no information available on the passage of Omeprazole into breast milk or its effects on the neonate, breast-feeding should be discontinued if the use of Omeprazole is considered essential, safety and effectiveness not established in pediatric patients less than 18 years of age.

Precautions & Warnings

Avoid concomitant use of clopidogrel and Xelopes
PPI therapy may be associated with an increased risk for osteoporosis-related fractures
Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with Xelopes
Concomitant use of PPIs with methotrexate may lead to methotrexate toxicities